Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 21, 2004. The report details changes in director interests in Ordinary Share American Depositary Receipts (ADRs) resulting from dividend reinvestment plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share ownership changes and specific transaction prices for ADRs.
- ADR Transaction Prices: $42.75, $42.125, and $42.66 per ADR depending on the specific plan.
- Dividend Date: April 15, 2004.
Material Changes
The filing reports increases in beneficial interests for specific directors due to the reinvestment of dividends paid on April 15, 2004. No material changes to the company's financial position or operations are disclosed in this text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to administrative notifications regarding director shareholdings.
Important Facts for Investors
- Director Share Increases: Directors D.F. McHenry, J.H. McArthur, J.P. Garnier, and T. Yamada increased their ADR holdings.
- Source of Increase: All reported changes stem from dividend reinvestment through various plans (US Global BuyDirect, Mid-Term Incentive Plan, Executive Supplemental Savings Plan, and Performance Share Plan).
- Valuation Context: The transactions occurred at prices ranging between $42.125 and $42.75 per ADR.
- Reporting Limitation: This document does not contain financial performance data for the period.